Cargando…

The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa

BACKGROUND: Retinitis pigmentosa (RP) is an inherited human retinal disorder that causes progressive photoreceptor cell loss, leading to severe vision impairment or blindness. However, no effective therapy has been established to date. Although genetic mutations have been identified, the available c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Tetsu, Ozawa, Yoko, Suzuki, Keiichiro, Yuki, Kenya, Ohyama, Manabu, Akamatsu, Wado, Matsuzaki, Yumi, Shimmura, Shigeto, Mitani, Kohnosuke, Tsubota, Kazuo, Okano, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058693/
https://www.ncbi.nlm.nih.gov/pubmed/24935155
http://dx.doi.org/10.1186/1756-6606-7-45
_version_ 1782321159649361920
author Yoshida, Tetsu
Ozawa, Yoko
Suzuki, Keiichiro
Yuki, Kenya
Ohyama, Manabu
Akamatsu, Wado
Matsuzaki, Yumi
Shimmura, Shigeto
Mitani, Kohnosuke
Tsubota, Kazuo
Okano, Hideyuki
author_facet Yoshida, Tetsu
Ozawa, Yoko
Suzuki, Keiichiro
Yuki, Kenya
Ohyama, Manabu
Akamatsu, Wado
Matsuzaki, Yumi
Shimmura, Shigeto
Mitani, Kohnosuke
Tsubota, Kazuo
Okano, Hideyuki
author_sort Yoshida, Tetsu
collection PubMed
description BACKGROUND: Retinitis pigmentosa (RP) is an inherited human retinal disorder that causes progressive photoreceptor cell loss, leading to severe vision impairment or blindness. However, no effective therapy has been established to date. Although genetic mutations have been identified, the available clinical data are not always sufficient to elucidate the roles of these mutations in disease pathogenesis, a situation that is partially due to differences in genetic backgrounds. RESULTS: We generated induced pluripotent stem cells (iPSCs) from an RP patient carrying a rhodopsin mutation (E181K). Using helper-dependent adenoviral vector (HDAdV) gene transfer, the mutation was corrected in the patient’s iPSCs and also introduced into control iPSCs. The cells were then subjected to retinal differentiation; the resulting rod photoreceptor cells were labeled with an Nrl promoter-driven enhanced green fluorescent protein (EGFP)-carrying adenovirus and purified using flow cytometry after 5 weeks of culture. Using this approach, we found a reduced survival rate in the photoreceptor cells with the E181K mutation, which was correlated with the increased expression of endoplasmic reticulum (ER) stress and apoptotic markers. The screening of therapeutic reagents showed that rapamycin, PP242, AICAR, NQDI-1, and salubrinal promoted the survival of the patient’s iPSC-derived photoreceptor cells, with a concomitant reduction in markers of ER stress and apoptosis. Additionally, autophagy markers were found to be correlated with ER stress, suggesting that autophagy was reduced by suppressing ER stress-induced apoptotic changes. CONCLUSION: The use of RP patient-derived iPSCs combined with genome editing provided a versatile cellular system with which to define the roles of genetic mutations in isogenic iPSCs with or without mutation and also provided a system that can be used to explore candidate therapeutic approaches.
format Online
Article
Text
id pubmed-4058693
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40586932014-06-17 The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa Yoshida, Tetsu Ozawa, Yoko Suzuki, Keiichiro Yuki, Kenya Ohyama, Manabu Akamatsu, Wado Matsuzaki, Yumi Shimmura, Shigeto Mitani, Kohnosuke Tsubota, Kazuo Okano, Hideyuki Mol Brain Research BACKGROUND: Retinitis pigmentosa (RP) is an inherited human retinal disorder that causes progressive photoreceptor cell loss, leading to severe vision impairment or blindness. However, no effective therapy has been established to date. Although genetic mutations have been identified, the available clinical data are not always sufficient to elucidate the roles of these mutations in disease pathogenesis, a situation that is partially due to differences in genetic backgrounds. RESULTS: We generated induced pluripotent stem cells (iPSCs) from an RP patient carrying a rhodopsin mutation (E181K). Using helper-dependent adenoviral vector (HDAdV) gene transfer, the mutation was corrected in the patient’s iPSCs and also introduced into control iPSCs. The cells were then subjected to retinal differentiation; the resulting rod photoreceptor cells were labeled with an Nrl promoter-driven enhanced green fluorescent protein (EGFP)-carrying adenovirus and purified using flow cytometry after 5 weeks of culture. Using this approach, we found a reduced survival rate in the photoreceptor cells with the E181K mutation, which was correlated with the increased expression of endoplasmic reticulum (ER) stress and apoptotic markers. The screening of therapeutic reagents showed that rapamycin, PP242, AICAR, NQDI-1, and salubrinal promoted the survival of the patient’s iPSC-derived photoreceptor cells, with a concomitant reduction in markers of ER stress and apoptosis. Additionally, autophagy markers were found to be correlated with ER stress, suggesting that autophagy was reduced by suppressing ER stress-induced apoptotic changes. CONCLUSION: The use of RP patient-derived iPSCs combined with genome editing provided a versatile cellular system with which to define the roles of genetic mutations in isogenic iPSCs with or without mutation and also provided a system that can be used to explore candidate therapeutic approaches. BioMed Central 2014-06-16 /pmc/articles/PMC4058693/ /pubmed/24935155 http://dx.doi.org/10.1186/1756-6606-7-45 Text en Copyright © 2014 Yoshida et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yoshida, Tetsu
Ozawa, Yoko
Suzuki, Keiichiro
Yuki, Kenya
Ohyama, Manabu
Akamatsu, Wado
Matsuzaki, Yumi
Shimmura, Shigeto
Mitani, Kohnosuke
Tsubota, Kazuo
Okano, Hideyuki
The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
title The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
title_full The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
title_fullStr The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
title_full_unstemmed The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
title_short The use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
title_sort use of induced pluripotent stem cells to reveal pathogenic gene mutations and explore treatments for retinitis pigmentosa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058693/
https://www.ncbi.nlm.nih.gov/pubmed/24935155
http://dx.doi.org/10.1186/1756-6606-7-45
work_keys_str_mv AT yoshidatetsu theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT ozawayoko theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT suzukikeiichiro theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT yukikenya theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT ohyamamanabu theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT akamatsuwado theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT matsuzakiyumi theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT shimmurashigeto theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT mitanikohnosuke theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT tsubotakazuo theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT okanohideyuki theuseofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT yoshidatetsu useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT ozawayoko useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT suzukikeiichiro useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT yukikenya useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT ohyamamanabu useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT akamatsuwado useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT matsuzakiyumi useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT shimmurashigeto useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT mitanikohnosuke useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT tsubotakazuo useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa
AT okanohideyuki useofinducedpluripotentstemcellstorevealpathogenicgenemutationsandexploretreatmentsforretinitispigmentosa